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by Jakovljevic M, Getzen TE. Front Pharmacol (2016) 7:21. doi:10.3389/fphar.2016.00021
The paper by Jakovljevic and Getzen highlighted the fact that low- and middle-income countries 
have been grabbing an ever larger share of global health spending over the last couple of decades (1). 
Share of global health spending of low- and middle-income countries as of 1995 expressed in million 
current PPP international $US grew from 26.1% in 1995 to 39.7% in 2013 (1). These countries are 
led by nations of BRICS (Brazil, Russia, India, China, and South Africa), followed by Next-11 nations 
(Bangladesh, Egypt, Indonesia, Iran, Mexico, Nigeria, Pakistan, the Philippines, Republic of Korea 
(South Korea), Turkey, and Vietnam) with a joint contribution to the global total health expenditure 
several times below the one of BRICS (1–5). Low- and middle-income countries, which represent 
an immense range of health system contexts, are likely to have more significant contribution in the 
global health-care market in the future as it is estimated that per-capita health spending will increase 
annually by 2.4, 3.0, and 3.4% in low-, lower-middle-, and upper-middle-income countries by 2040, 
respectively (1, 6). For high-income countries this rate is estimated at 2.7% (6).
One interesting question can be raised. What is happening with population health outcomes 
in low- and middle-income countries as health expenditure is increasing? The authors mentioned 
that “substantial gains in overall welfare are reflected in the expansion of health insurance coverage 
and diversity of medical services provided” (1). Some other aspects would also be valuable for 
discussion.
First, determining the impact of health expenditure on health outcomes is a challenging 
and complex issue as health outcomes are determined by a vast number of socioeconomic and 
environmental factors (7–9). Solely increasing public health expenditure, may not significantly 
affect health outcomes if its efficiency is inadequate (8, 9). It has been suggested that, on average, 
inefficiency of allocating health expenditures in emerging and developing economies is highest 
in Africa, while Western Hemisphere and Asian economies are relatively more efficient, with 
significant variations within the aforementioned regions (8). One systematic review has shown 
that private health-care system sectors in low- and middle-income countries appear to have 
lower efficiency compared to public sector as a result of weak regulation, higher costs of drugs, 
improper incentives for unnecessary testing, and treatment, but that, on the other hand, public 
sector tends to be less responsive to patients and susceptible to the lack of availability of supplies 
(10). Higher public health expenditure is generally associated with better health outcomes, but 
still there are substantial differences within the emerging and developing economies groups 
(8). The relationship between public health expenditure and health-adjusted life expectancy, 
as well as immunization rates, is generally found to be positive and significant, whereas it is 
negative and significant with mortality rates (8). For example, favorable effect of higher public 
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health expenditure on mortality under 5  years is significantly 
larger for low- and middle-income countries (11). However, 
this might not be applicable to all low- and middle-income 
settings. In some African countries, like Nigeria, increasing 
public health expenditure alone, without properly addressing 
issue of corruption, is not enough to lead to improvement in 
population health status (12).
Health-care quality improvement is very important for 
improving population health outcomes (13). However, it has 
been shown that increasing health-care expenditure does not 
necessarily reflect increasing quality of delivered health care 
(14, 15). The evidence from BRICS nations confirms that sole 
increase in public health expenditure cannot assure better health 
outcomes unless the quality of delivered health care is substan-
tially improved (9). Even in the United States, where per-capita 
spending on health care is estimated to be 50–200% greater than 
in other developed countries, this does not yield much better 
health outcomes compared to other OECD countries (16) and 
higher spending is not highly correlated with the quality of care, 
as price of the same service may vary and expensive new thera-
pies may be adopted without good evidence that they improve 
patient outcomes (17).
In 2012, International Journal for Quality in Health Care 
dedicated a special issue to address status of health-care quality 
improvement research in low- and middle-income countries 
with many papers that highlighted that “much remains to be 
studied and understood to optimally promote quality improve-
ment” (18). Data on quality of health-care services in low- and 
middle-income countries are scarce, probably due to the past 
emphasis on health-care coverage rather than the quality of 
provided care and insufficient validation of the existing quality 
measures (19). Quality assessment in terms of infrastructure and 
staffing, technical quality, and patients’ experiences was not done 
consistently in low- and middle-income countries, thus compar-
ing of measurements made in different settings is difficult (19). 
A  systematic review based on limited data from comparative 
studies conducted in low- and middle-income countries sug-
gested that the quality of private and public ambulatory care is 
similarly low in terms of infrastructure, clinical competence, and 
practice for both types of providers, although private sector tends 
to perform better in drug availability and aspects of delivery of 
care, such as responsiveness and effort (20).
Increasing burden of rising incidence of non-communicable 
diseases and accelerated population aging in low- and middle-
income countries will pose a major problem for national 
policy makers (21–29). As Jakovljevic and Getzen pointed 
out, achievement of universal health coverage, types, and 
costs of services covered by basic insurance package will 
certainly remain the major imperatives for national policy 
makers of these countries (1). Governments will also need a 
comprehensive approach in order to develop and implement 
effective strategies to ensure adequate efficiency of forecast 
increase in health spending along with improving quality of 
care. Policy lessons from high-income countries may be useful, 
but they might not transfer well to all low- and middle-income 
countries’ settings due to the key context differences regarding 
widespread poverty and relative weakness of political and social 
institutions (15). In order to develop successful approaches, 
countries should take into consideration their own specific 
circumstances after careful evaluation and prioritization of 
underlying problems.
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